Tatiana Prowell: Things to consider when evaluating PFS benefit
Tatiana Prowell, Associate Professor of Oncology at Johns Hopkins School of Medicine and Breast Cancer Scientific Liaison at the U.S. Food & Drug Administration, shared a post on X:
“Things to consider when evaluating PFS benefit:
Is this an add-on (A+B vs A) or a replacement design (A vs B) where A is std of care.
If add-on, PFS benefit must be larger to offset added tox/cost of a combo & result in benefit/risk.”
“In contrast, if a replacement trial shows superiority, a smaller PFS benefit may be meaningful, especially if there is another advantage such as more favourable toxicity profile, greater patient convenience, etc.
HOWEVER…”
“You must ask:
What is the absolute benefit in PFS & how does it compare to imaging interval? (Note scans may get less frequent w/ time in trials so on that too dep on mPFS).
If mPFS diff is < time btwn scans, hard to know if real.”
More posts featuring Tatiana Prowell.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023